ClinicalTrials.gg
CompletedNCT00305435Updated Jul 5, 2024

Safety Study of AMG 531 in Japanese Subjects With ITP

A Phase 2 interventional study of Romiplostim (AMG-531) in Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), sponsored by Kyowa Kirin Co., Ltd.. Completed. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing romiplostim in Purpura, Thrombocytopenic — 1 open to participants now, 1 under way, none of them phase 3. romiplostim · Purpura, Thrombocytopenic.

Enrollment
11th of 11
12 · median 62
Started
2006
with 2 others
Phase 2
Only one
of the 11
Registered
5th of 11
by date
Lead sponsor
2 of 11
Kyowa Kirin Co., Ltd.

Among the 11 studies testing romiplostim in Purpura, Thrombocytopenic, this one is the 11th largest by enrollment, is one of 3 that started in 2006, is the only one in phase 2, and was the 5th registered.

Purpura, Thrombocytopenic

32 studies on the registry are indexed under Purpura, Thrombocytopenic; 6 are open to participants now.

Browse Purpura, Thrombocytopenic studies →

Open to participants now

1 of the 11 studies testing romiplostim in Purpura, Thrombocytopenic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 4 Purpura, Thrombocytopenic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing romiplostim in Purpura, Thrombocytopenic, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy of starting dose of AMG 531 as measured by platelet counts by cohort dose-escalation design.

Read the detailed description

The purpose of the study is to evaluate the efficacy of starting dose of AMG 531 as measured by platelet counts by cohort dose-escalation design.

03

Conditions studied

  • Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Keywords

  • AMG 531, ITP, Phase 2, Japanese
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Japanese patients with diagnosis of ITP according to the diagnostic criteria proposed by Research Committee for Idiopathic Hematopoietic Disorders of the Ministry of health, labor and welfare Exclusion Criteria: - Documented diagnosis of arterial thrombosis in the previous year; history of venous thrombosis and receiving anticoagulation therapy

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    romiplostim (AMG-531)

    Drug: Romiplostim (AMG-531)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of all adverse events including evaluation of antibody status

    Time frame: 1 year

Secondary outcomes

  1. Proportion of subjects who achieve a platelet response

    Time frame: 2 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, Iwato K, Ohtsu T, Berger DP. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009 Sep;90(2):157-165. doi: 10.1007/s12185-009-0361-y. Epub 2009 Jun 20. PubMed 19543952 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2006
First posted
Mar 22, 2006
Start
Feb 2006
Primary completionActual
Nov 2006
CompletionActual
Nov 2006
Last update
Jul 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00305435
Responsible party
Sponsor
First posted
Mar 22, 2006
Start date
Feb 2006
Primary completion
Nov 2006
Completion
Nov 2006
Last update
Jul 5, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion